PBE ETF (Invesco Biotechnology and Genome ETF) is managed by Invesco (US) with $247.5M in net assets. PBE expense ratio is 0.58%, holding 33 positions across sectors including Health Care, Financials, Unknown. Inception date: 2005-06-23.

PBE performance shows a YTD return of -0.43%. The 1-year return is 24.22% and the 5-year return is 2.26%. PBE dividend yield stands at 1.00%, paid quarterly.

PBE top holdings include Illumina, Inc. (5.1%), United Therapeutics Corp (5.0%), Regeneron Pharmaceuticals, Inc. (5.0%), Biogen Inc. Com (4.9%), Amgen Inc. (4.8%). View all PBE holdings, sector breakdown, or dividend history.

PBE can be compared against other funds using the overlap calculator or side-by-side comparison tool. PBE alternatives are available via the screener, along with tax-loss harvesting opportunities.